Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Myeloproliferative Neoplasm. Basic parameters: 0 years — 30 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications
Overview
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
Primary outcome measures
- Describe the epidemiological characteristics of the study population [Time frame: at enrollment]
- Describe the mutational landscape of these MPNs [Time frame: at enrollment]
Secondary outcome measures (3)
- Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1 [Time frame: At 10 years]
- Describe the classical MPN outcomes-2 [Time frame: At 10 years]
- Describe the classical MPN outcomes-3 [Time frame: At 10 years]
Eligibility criteria
Inclusion criteria
- Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria.
- Signature of the consent form for participation in the FIMBANK project.
- Agreement to participate in the VYP study.
- Patient of legal age at the time of inclusion in VYP.
- Patient affiliated to a social security scheme
Exclusion criteria
- Refusal to participate by patients of full age
- Patient under legal protection (guardianship, curatorship, etc.)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
France · 1 center
- CHU de Brest — Brest
Identifiers
NCT: NCT06715267 · 29BRC23.0018 - VYP